---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-031615"
form_type: "8-K"
ticker: "ATXI"
cik: "0001644963"
company_name: "AVENUE THERAPEUTICS, INC."
filed_at: "2023-11-13T23:59:59+00:00"
generated_at: "2026-06-08T05:14:58.611621+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Avenue Therapeutics reports Q3 net income of $0.5M; cash low, raises $5M

## Summary
- Net income $0.5M ($0.06 per share) vs net loss $0.7M in Q3 2022; R&D $0.9M, G&A $1.2M.
- Cash $0.2M at Sep 30, 2023; completed $5M public equity offering in Nov 2023.
- AJ201 Phase 1b/2a enrollment on track; topline data expected Q2 2024.
- BAER-101 preclinical results accepted for AES meeting; IV tramadol Phase 3 design agreed with FDA.
- IV tramadol Phase 3 safety study pending additional financing; aim to start as soon as feasible.

## SEC filing metadata
- accession: 0001437749-23-031615
- form_type: 8-K
- ticker: ATXI
- cik: 0001644963
- company_name: AVENUE THERAPEUTICS, INC.
- filed_at: 2023-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1644963/000143774923031615/0001437749-23-031615-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1644963/000143774923031615/atxi20230822_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-031615
- JSON: https://secwatch.observer/filing/0001437749-23-031615.json
- Plain text: https://secwatch.observer/filing/0001437749-23-031615.txt

## Key facts
- Earnings Releases
  AVENUE THERAPEUTICS, INC. reported the third quarter ended September 30, 2023 results: net income Net income attributable to common stockholders for the third quarter of 2023 was $0.5 million, or $0.06 per share, EPS $0.06 per share.
  - Period: the third quarter ended September 30, 2023
  - Net income: Net income attributable to common stockholders for the third quarter of 2023 was $0.5 million, or $0.06 per share
  - EPS: $0.06 per share
  - Result: reported results
  source text: On November 13, 2023, Avenue Therapeutics, Inc. (the “Company” or “Avenue”) issued a press release to provide a corporate update and to announce its financial results for the three months ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1644963/000143774923031615/0001437749-23-031615-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.